Consequences of an Interruption. 10.6.1 For purposes of this Agreement, an “Interruption” shall be deemed to have occurred in any of the following circumstances: (a) with respect to either the Primary Program or the Alternate Program, considered separately, if at any time after the Research Termination Date and before a Drug Product is achieved, Vertex or its Affiliates, licensees, sublicensees, assignees or partners (collectively, and for purposes of this Section
Appears in 4 contracts
Samples: Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)
